Related Experiment Video

Updated: Aug 17, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction

G J Macphee, G T McInnes, G G Thompson

    Lancet (London, England)
    |March 29, 1986
    PubMed

    More Related Videos

    Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

    Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

    Published on: May 16, 2019

    Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique08:11

    Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

    Published on: November 11, 2022

    Related Concept Videos

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

    Antiepileptic Drugs: GABAergic Pathway Potentiators

    γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
    The key GABA pathway potentiators used in epilepsy management are as follows.
    Benzodiazepines are a well-known class of drugs used for their...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Antiepileptic Drugs: Potassium Channel Activators01:20

    Antiepileptic Drugs: Potassium Channel Activators

    Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
    Ezogabine has gained approval as an adjunctive treatment...
    Pharmacokinetics: Drug–Drug Interactions01:25

    Pharmacokinetics: Drug–Drug Interactions

    Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
    Drug toxicity: Drug–Drug Interaction01:30

    Drug toxicity: Drug–Drug Interaction

    Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...